Laboratory Corp of America Holdings - Company Profile
Powered by
All the data and insights you need on Laboratory Corp of America Holdings in one report.
- Save hours of research time and resources with
our up-to-date Laboratory Corp of America Holdings Strategy Report
- Understand Laboratory Corp of America Holdings position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a range of diagnostic technologies and testing services. The company offers clinical diagnostics laboratory services such as core testing, genomic and esoteric testing. Its services include general and specialty laboratory testing, bone marrow and human leukocyte antigen (HLA) testing, clinical trials services, drug testing services, deoxyribonucleic acid (DNA) identification services, forensic identity services, insurance health plan services, paternity testing services, patient services, personalized medicine, and hospital services. It also offers drug development services through Covance. It offers services to managed care organizations, hospitals, physicians, government agencies, and biotechnology and pharmaceutical companies through a network of primary laboratories and patient service centers. The company has operations across the US, Belgium, China, Singapore, the UK, and other countries. LabCorp is headquartered in Burlington, North Carolina, the US.
Laboratory Corp of America Holdings premium industry data and analytics
Products and Services
Services | Brands |
---|---|
- | - |
LabCorp | LabCorp Link |
Ambulatory Monitoring Services | AccuDraw |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Plans/Strategy | In April, the company announced its plans to acquire assets from Invitae Corp through a voluntary bankruptcy protection process for US$239 million. |
2024 | Asset Purchase | In April, the company acquired Providence Oregon's outreach laboratory business and select assets in Oregon, the US. |
2024 | Regulatory Approval | In April, the company received approval from the U.S. Food and Drug Administration for its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic for treatment with BEQVEZ. |
Competitor Comparison
Key Parameters | Laboratory Corp of America Holdings | IQVIA Holdings Inc | Quest Diagnostics Inc | ICON Plc | Sonic Healthcare Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | Ireland | Australia |
City | Burlington | Durham | Secaucus | Dublin | Sydney |
State/Province | North Carolina | North Carolina | New Jersey | Dublin | New South Wales |
No. of Employees | 67,000 | 87,000 | 40,000 | 41,100 | 41,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Adam H. Schechter | Chairman; Chief Executive Officer; President | Executive Board | 2020 | 59 |
Glenn A. Eisenberg | Executive Vice President; Chief Financial Officer | Senior Management | 2014 | 62 |
Mark S. Schroeder | Executive Vice President; President - Diagnostics Laboratory Operations and Global Supply Chain; Chief Operating Officer | Senior Management | 2019 | 63 |
Peter J. Wilkinson | Chief Accounting Officer; Senior Vice President | Senior Management | 2019 | 53 |
Amy B. Summy | Chief Marketing Officer; Executive Vice President | Senior Management | 2020 | 58 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer